Enavate Sciences Gp
Enavate Sciences Gp reported 8 stocks worth $280M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are ZBIO (28.1%), IMNM (27.8%) and BRVE (26.5%). Compared with Q2 2026, the fund opened new positions in BRVE and trimmed ZBIO and CAMP.
Latest filing: what Enavate Sciences Gp did in Q3 2026
vs Q2 2026Dollar changes use the share change at the quarter end price. New and sold out show the whole position.
Portfolio at a glance
share of reported value · Q3 2026Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 | ![]() ZBIO Zenas Biopharma Inc | $78.7M | 28.1% | 2.9M | −1M (−26%) | 8 of 8 | |
| 2 | ![]() IMNM Immunome Inc | $77.7M | 27.8% | 3.6M | No change | 8 of 8 | |
| 3 | ![]() BRVE Braveheart Bio Inc | $74.2M | 26.5% | 3.7M | New position | 1 of 8 | |
| 4 | ![]() SION Sionna Therapeutics Inc | $13M | 4.7% | 2.5M | No change | 7 of 8 | |
| 5 | ![]() UPB Upstream Bio Inc | $13M | 4.6% | 2.5M | No change | 8 of 8 | |
| 6 | ![]() BBOT Bridgebio Oncology Therapeut | $10.8M | 3.9% | 2.6M | No change | 5 of 8 | |
| 7 | ![]() CMPX Compass Therapeutics Inc | $8.1M | 2.9% | 7.8M | No change | 8 of 8 | |
| 8 | ![]() CAMP CAMP4 Therapeutics Corp | $4.2M | 1.5% | 1M | −384K (−27%) | 8 of 8 |
Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.
Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q3 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Nov 16, 2026 | 13F-HR | Q3 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Enavate Sciences Gp 13F FAQ
What does Enavate Sciences Gp own?
Enavate Sciences Gp reported 8 stocks worth $280M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are ZBIO (28.1%), IMNM (27.8%) and BRVE (26.5%). The table above lists every position in the filing (the top 10 without an account).
What did Enavate Sciences Gp buy and sell in Q3 2026?
Compared with Q2 2026: 1 new positions, 0 added to, 2 trimmed and 0 sold out. New positions include BRVE.
When will Enavate Sciences Gp file its next 13F?
Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.
How much is Enavate Sciences Gp's portfolio worth?
The Q3 2026 filing reports $280M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.







